Background--Epicardial adipose tissue (EAT) is hypothesized to alter atherosclerotic plaque composition, with potential development of high-risk plaque (HRP). EAT can be measured by volumetric assessment (EAT-v) or linear thickness (EAT-t). We performed a systematic review and random-effects meta-analysis to assess the association of EAT with HRP and whether this association is dependent on the measurement method used.
picardial adipose tissue (EAT) is a metabolically active fat depot, abundant in proinflammatory cytokines, and has been correlated with the extent and severity of coronary artery disease (CAD). 1 EAT shares the same embryologic origin of omental and mesenteric fat 2, 3 and encases the coronary arteries with no fascial barrier. 4 Consequently, it has been postulated that EAT may display vasocrine or paracrine effects on the adjacent arterial wall to influence atherosclerotic plaque composition, resulting in the development of high-risk plaque (HRP). [5] [6] [7] [8] [9] The presence of HRP has shown association with future adverse prognosis, 10, 11 but the management of these patients remains uncertain. HRP may be visualized invasively by several methods including intravascular ultrasound and optical coherence tomography and noninvasively by computed tomography (CT) coronary angiography with good diagnostic agreement between techniques. [12] [13] [14] EAT may be measured either volumetrically by CT coronary angiography or noncontrast CT (EAT-v) or by a linear thickness measurement on echocardiography (EAT-t). Both thickness and volume measures have been associated with incident CAD 1 ; however, linear thickness may underrepresent the totality of EAT. The objective of this systematic review and meta-analysis was to explore the association between EAT and the presence of HRP. The secondary aims were to evaluate whether increasing EAT volume is associated with HRP presence and
Study Selection
The following inclusion criteria were used for the study: patients undergoing either intracoronary imaging or CT coronary angiography evaluation with reported HRP features, noninvasive measurement of EAT by either CT-derived volume (on contrast or noncontrast CT) or linear thickness (by CT or echocardiography), and reports fully published in peerreviewed journals. For intracoronary imaging studies, HRP was defined as the presence of thin-cap fibroatheroma. For CT studies, HRP included plaques with ≥1 of the following features: low-attenuation plaque, positive remodeling, spotty calcification, and the napkin ring sign. Study specific definitions of HRP are reported in Table S2 .
Data Extraction
Odds ratios (ORs) and their respective 95% confidence intervals (95% CIs) for association of EAT with HRP were extracted. If possible, ORs from multivariable models that adjusted for other CAD risk factors were used, and covariates within the model were recorded. Mean and standard deviation of EAT volume between groups with and without HRP were entered. Studies reporting medians with interquartile ranges were converted to means, as recommended previously. 15 
End Points
The primary end point was the pooled association of EAT with the presence of HRP. Secondary end points included the pooled quantitative difference of EAT-v in patients with and without HRP and the association of EAT with HRP stratified by EAT measurement method (EAT-v or EAT-t).
Statistical Analysis
Statistical analysis was performed using StataMP 14.0 (StataCorp). ORs were examined on the log scale and transformed for graphical presentation with 95% CI reported. If multiple outcomes were reported (ie, by individual plaque feature or by grouped features), the analyzed estimate was the association of EAT with any HRP if specified. Random-effects modeling was used with the method of DerSimonian and Laird. 16 The weighted mean difference for EAT between groups with and without HRP was calculated. Statistical heterogeneity was evaluated by the I 2 statistic and quantified as low (<25%), moderate (25-75%), or high (>75%). 17 Sensitivity analysis was performed by EAT measurement method (EAT-v or EAT-t, by pooled estimates of similarly defined EAT covariate parameters; ie, when EAT was included as a continuous variable or assessed in 10-mL increments and for individual plaque features, if possible). Additional sensitivity analysis using random effects with the Hartung-Knapp-Sidik-Jonkman (HKSJ) approach was used to explore effect sizes when 2 studies were grouped. 18, 19 Exploratory metaregression was performed to assess the influence of independent variables (mean study ages, mean EAT volume, mean study body mass index, and proportion of HRP). Publication bias was assessed by the Egger and Begg test. In addition, the Duval and Tweedie trim-and-fill method was used to investigate publication bias,
Clinical Perspective
What Is New?
• Increasing epicardial adipose tissue (EAT) volume is associated with the presence of high-risk coronary artery plaque characteristics.
• Patients with high-risk coronary plaque features have quantitatively higher EAT volumes.
• EAT should ideally be measured by complete volumetric analysis rather than by linear thickness measurements.
What Are the Clinical Implications?
• Incorporation of EAT measurement with routinely performed cardiac computed tomography may assist in improved risk stratification for patients.
• EAT may represent an important cardiovascular therapeutic target.
and systematic exclusion of individual studies was used to assess changes in the pooled estimate. A 2-sided P value of <0.05 was considered significant.
Results
A total of 90 publications were reviewed with 9 studies included for final analysis (3772 participants; Figure 1 ). One study was excluded because it presented the association of EAT with plaque lipid percentage rather than specified numbers of patients with HRP. 20 Seven studies reported CT assessment of HRP [21] [22] [23] [24] [25] [26] [27] (n=3573) and 2 studies reported invasive assessment of HRP 29,30 (n=199) . Seven studies measured EAT-v [21] [22] [23] [24] [25] [26] 29, 30 (n=3284), and 2 studies measured EAT-t 27,28 (n=488). All study designs were cross-sectional. All patients were from cohorts with suspected CAD, with 2 studies evaluating patients with suspected acute coronary syndrome. 21, 22 Study characteristics are presented in Tables 1 and 2 , and regression modeling outcomes and model covariates are presented in Table 3 . Individual-study EAT measurement characteristics and HRP definitions are presented in Table S2 .
The prevalence of HRP ranged widely, from 4% to 59% at a per-patient level ( Figure 4 ). This remained statistically nonsignificant on sensitivity analysis with the HKSJ method ( Table 4) . Sensitivity analysis was performed to assess pooled estimates of studies using EAT as a similarly measured covariate. Two studies analyzed EAT-v in 10-mL increments and demonstrated a pooled OR of 1.18 (95% CI, 1.12-1.24; The results for both low-attenuation plaque and positive remodeling became statistically nonsignificant after application of the HKSJ method, but the presence of both features remained significantly associated with increasing EAT ( (Table S3 ).
Discussion
The results from this meta-analysis of 9 observational studies demonstrate 3 important findings. First, increasing EAT is chemoattractant protein 1, IL-6 (interleukin 6). IL-1b, IL-6sR, and tumor necrosis factor a. 31 Because of EAT's anatomic proximity to the adjacent myocardium and lack of fascial barrier with the epicardial coronary arteries, there may be paracrine or vasocrine signaling of cytokines between the surrounding fat and the underlying arterial wall. 2 This suggested pathophysiology is analogous to the visceral intra-abdominal adipose tissue surrounding the portal circulation that is purported to influence the development of hepatic steatosis. 32 It has been demonstrated that increased EAT volume is related to both the extent and the lesion severity of coronary stenosis 33 and that EAT contains a greater amount of inflammatory cytokines than serum circulating levels and subcutaneous adipose stores. 34 The apposition of EAT with the arterial adventitia suggests the "outsidein" hypothesis of atherosclerosis, whereby the inflammatory milieu of EAT leads to vascular inflammation of the adventitia progressing inward to the intima, leading to plaque formation. Consequently, it is possible that cellular cross-talk may lead to the development of plaque characteristics considered to be "high risk" given their association with major adverse cardiovascular events. It has also been reported that high EAT levels are associated with mortality, although it remains unclear whether these levels are specifically related to preceding cardiovascular events. 35 Our results indicate a uniform association of increasing EAT with HRP, but further study is needed to establish the influence and interaction of these parameters with prognosis. Importantly, we aimed to use risk estimates from multivariable models, which suggests an incremental effect of EAT with HRP presence beyond traditional cardiovascular risk factors. Because there is no guideline-advocated technique for EAT quantification, individual studies are subject to authors' discretion and experience. The interobserver variability for EAT-t has shown mixed results, 36 and a measure of linear thickness by 2-dimensional assessment may under-or overrepresent total EAT volume due to changes in probe angulation. It has been suggested that a threshold of 7 mm confers elevated EAT-t; this is a significantly higher threshold than our included studies and may also influence interpretation. Only 1 previous study evaluated EAT-t versus EAT-v, in 71 patients, and reported a modest correlation (r=0.595). EAT-v, however, also has limitations, with differing values measurable with the use of contrast media 38 and possible differences related to vendor-specific software algorithms. In our analysis of EAT-v versus EAT-t, we demonstrated that EATt had a decidedly wide CI for the association with HRP and failed to reach statistical significance, although this is based on only 2 studies with a total of 488 patients. On the contrary, EAT-v displayed a significant association with HRP with more precise confidence limits. We attempted to explore the association further by analyzing the modeling method of EAT, which demonstrated uncertainty in estimates for differing techniques and highlighted the need for a standardized and consistent approach when incorporating EAT into models to assess disease outcomes. In our subgroup analysis of EAT association with HRP subtype, we noted a strong association individually with lowattenuation plaque and positive remodeling as well as with the presence of both features after adjustment for conventional cardiovascular risk factors. Association with individual plaque feature types diminished due to imprecision in 95% CIs but remained for the presence of both high-risk features. The largest study to date, of 3158 patients by Motoyama et al, reported that these HRP characteristics, defined as the presence of either feature or both, are strongly associated with future acute coronary syndrome development (adjusted hazard ratio: 8.24 [95% CI, 5.26-12.96]; P<0.001).
10 EAT was not measured in this study, and its contribution to prognosis remains unclear. It is notable that some observational studies have demonstrated a lack of relationship between EAT and significant CAD 39, 40 -similar to our included studies, all of which are observational and prone to significant bias. Biases include selection and ascertainment bias and variable use of predictors in regression modeling that may alter reported estimates and contribute to between-study heterogeneity. To assess study quality, we evaluated the Grading of Recommendations Assessment, Development and Evaluation (GRADE) classification [41] [42] [43] (Tables S4 and S5), which apportions an overall study-quality assessment. Because none of the trials are, by definition, of high quality, given that they are not randomized controlled trials, the overall information quality is regarded as low and should be interpreted as such without drawing firm conclusions that may alter clinical decision making. Despite the inconsistency of CAD association, given the association of HRP with cardiac prognosis, it remains plausible that EAT may influence plaque composition that may not be diagnosed as functionally or anatomically significant. Rigorous prospective study to assess the role of EAT in atherogenesis is still warranted.
The management of HRP features is uncertain. EAT is currently measured only for research purposes; however, the importance of assessing EAT and its association with HRP relates to a potential target for therapeutic intervention. EAT has demonstrated temporal changes in plaque and cardiovascular risk. In a study of nonobese patients undergoing serial CT over 4 years, an increase in EAT volume was associated with HRP as well as future acute coronary syndrome despite optimal management of cardiovascular risk factors. 44 Calorie restriction and bariatric surgery rather than exercise have shown promise as methods for EAT reduction, as explored recently in a meta-analysis by Rabkin and Campbell, 45 and animal data have demonstrated that selective surgical excision of EAT slows the progression of atherosclerosis. 46 It remains to be seen whether targeted EAT reduction may improve dynamic atherosclerosis in human participants, and randomized controlled trial data are lacking.
Study Limitations
Our analysis is limited by the observational nature of included studies and by a lack of access to patient-level data to allow adjustment for other covariates that may influence EAT including sex differences and stratification and assessment by other population features such as traditional cardiovascular risk factors of hypertension, hyperlipidemia and diabetes mellitus. We attempted to account for this by using model estimates that adjusted for several of these variables. The majority of studies were also performed in Japanese centers, which may limit the generalizability of our findings to other ethnic populations. Another important limitation is the inclusion of only 2 studies evaluating EAT thickness and other subgroup parameters. The interpretation of results is limited by this methodology because of the potential lack of power and the inability to draw firm conclusions. Importantly, we noted that when more robust statistical methods were applied when few studies were pooled, statistical significance was reversed, highlighting the need for more data in these areas. We noted a significant degree of heterogeneity, a limitation that has been demonstrated in other published EAT meta-analyses that report I 2 values >90%. 1, 47 This is probably in part representative of variable EAT quantification methods and differing measures of EAT as a covariate in regression analyses. We attempted to adjust for this heterogeneity by systematic exclusion of studies that did not significantly attenuate the summary estimates from statistical significance and by sensitivity analysis by subgroup analysis and exploratory metaregression. odds ratios and 95% confidence intervals (CIs) for the association of increasing EAT with high-risk plaque (HRP) stratified by measurement method of EAT measurement, either by volume or thickness. This demonstrates that increasing EAT volume has a significant association with HRP; however, increasing EAT thickness is not significantly associated with HRP and has a markedly wide CI crossing the line of unity. CACS indicates coronary artery calcium score (noncontrast computed tomography); CTCA, computed tomography coronary angiography; Echo, echocardiography.
Conclusion
Increasing EAT is associated with the presence of HRP, ideally, when measured by complete volumetric analysis. Further investigation is still required to establish the role of EAT-t in evaluating HRP and consistent methods for modeling EAT as a variable for disease outcomes and the effect of EAT on individual HRP features. Incorporating the measurement of EAT into clinically performed CT coronary angiography has the potential to improve patient risk stratification. Further prospective studies are needed to confirm this finding, which holds potential as a novel therapeutic target for atherosclerotic treatment.
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